Expanded funding RxFunction has secured multiple rounds of venture funding, including a $16.5M raise in 2024 and a prior $5M equity financing in 2022, signaling investor confidence and potential for scaled sales efforts and reimbursement discussions with payers and health systems.

Clinical value Walkasins provides clinically proven improvements in gait and balance and reduces fall risk for peripheral neuropathy patients, creating a strong value proposition for neurology, rehabilitation, and geriatrics departments and fall-prevention programs.

Direct channel focus RxFunction is the exclusive manufacturer and provider of Walkasins, with a prescription-only model that aligns with clinician-driven sales motions to secure placements in hospitals, clinics, and VA centers where specialist pathways exist.

Strategic partnerships Past collaborations with Liberating Technologies for balance and gait training systems suggest opportunities to bundle or co-market training programs with device deployment in neurorehabilitation and prosthetics clinics.

Growth potential With a relatively lean employee base and a market footprint in specialized medical devices, there is room to expand via targeted outreach to orthopedics, vascular neurology, physical therapy networks, and elder-care programs focusing on fall prevention.